AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion
Furthering cell therapy ambition across oncology and autoimmune diseases
Furthering cell therapy ambition across oncology and autoimmune diseases
Ami Organics will also sign an MoU with Government of Gujarat for investment amounting up to Rs 300 crores for set up of dedicated manufacturing facility for electrolytes business
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
This cell will serve as an extension of the Tele Mental Health Assistance and Networking Across States initiative of the Ministry of Health and Family welfare
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Subscribe To Our Newsletter & Stay Updated